2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Erminia Massarelli, MD, PhD, MS, discusses advances in front-line immunotherapy in non–small cell lung cancer.
Erminia Massarelli, MD, PhD, MS, co-director of the Lung Cancer and Thoracic Oncology Program, section chief of Thoracic Oncology, and associate professor in the Department of Medical Oncology and Therapeutics Research at City of Hope, discusses advances in frontline immunotherapy in non–small cell lung cancer (NSCLC).
Many novel immunotherapy combinations are emerging, such as those combining anti-TIGIT antibodies and LAG-3 inhibitors, Massarelli says. One combination currently being studied is that of an anti-TIGIT antibody and checkpoint inhibitor, which has shown promise in patients with PD-L1 levels of 50% or higher, Massarelli explains.
Other clinical trials studying immunotherapy include those looking at cell therapy in NSCLC, Massarelli notes. Combinations of immuno-oncology molecules with TKIs such as lenvatinib (Lenvima) are also promising, Massarelli concludes.